PixCell Medical, an Israeli innovator of rapid point-of-care (POC) diagnostic systems, announced Monday that the company has been presented with the 2021 MedTech Visionaries Awards in the categories of Best Medical Device and Best MedTech Visionary in the Field of Medical Devices for Real-Time Blood Testing.
PixCell won the awards for its novel blood testing platform, the HemoScreen, an easy-to-use, portable, and reliable instrument that allows real-time blood testing to be performed by anyone, anywhere, providing critical health data on the spot.
Indeed, according to a presentation that the company’s CEO and Co-Founder Avishay Bransky Ph.D. gave in July, PixCell has taken advantage of a revolution in cytometry (the measurement of the characteristics of cells – in this case blood cells). With the advent of more efficient processors due the the advancement in the smartphone industry especially with regard to cheaper cameras, the firm was able to develop imaging flow cytometry, which reduced the need for blood samples to be tested in a laboratory.
PixCell’s HemoScreen is the only 5-part differential complete blood count (CBC) analyzer that is both FDA-cleared and CE-marked for point-of-care use.
HemoScreen leverages patented technologies such as a novel microfluidics method, Viscoelastic Focusing, AI-powered machine vision and an innovative Lab-On-A-Cartridge concept to deliver lab-accurate results within five minutes, using just one drop of capillary blood. HemoScreen delivers accurate readings of 20 standard blood count parameters with the high sensitivity of centralized lab machinery.
The device has been successfully integrated into clinical workflows, eliminating the need for specially trained lab technicians to calibrate or operate it.
It has as already been integrated into hospitals and clinics around the world, as well as in homecare settings to remotely monitor chemotherapy patients as well as help to avoid potential exposure to COVID-19 and other pathogens in hospitals.
In May, South Korea-based semiconductor firm Soulbrain invested in PixCell Medical and acquired all of the company’s controlling shares.
“It is an honor to receive this recognition, and I am proud of the entire PixCell Medical team as we continue making strides in our global efforts to simplify blood testing,” said Bransky.
“PixCell was founded [in 2008] to resolve an important unmet need – to make the most common blood test simple and accessible everywhere. Until now, industry-standard technologies were based on outdated principles, slowing down diagnostics and delivery of treatment. Our breakthrough technologies enabled miniaturization and simplification of blood tests, providing highly accurate results immediately, in a significantly shorter amount of time, saving patients, clinicians and health systems both time and costs.”
The MedTech Visionaries Awards now in their second year accepts entries from around the world, which highlight the advancements and accomplishments of those disrupting the status quo in the MedTech industry.